Chicago, ILNCT07149363Now EnrollingIRB Ready

Small Cell Lung Cancer (SCLC) Clinical Trial in Chicago, IL

Access cutting-edge small cell lung cancer (sclc) treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Alliance Foundation Trials, LLC.

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access small cell lung cancer (sclc) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related small cell lung cancer (sclc) treatment provided free

Apply for This Chicago Location

Check if you qualify for this small cell lung cancer (sclc) clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Small Cell Lung Cancer (SCLC) Study in Chicago

This is a phase II trial of adjuvant chemotherapy and immunotherapy for completely resected small cell lung cancer (SCLC).

Sponsor: Alliance Foundation Trials, LLC.

Who Can Participate

Inclusion Criteria

Age ≥ 18 years.
Body weight \>30 kg.
Must have a life expectancy of at least 12 weeks.
Must have histologically or cytologically confirmed diagnosis of pathologic T1-T2 N0-1 M0 small-cell lung cancer per the American Joint Committee on Cancer staging system, 8th edition.
Have completely resected (wedge resection, segmentectomy, lobectomy, sleeve lobectomy, bilobectomy, or pneumonectomy) small-cell lung cancer within 78 days of enrollment.
Complete mediastinal lymph node dissection (MLND) or systematic mediastinal lymph node sampling is required.
No prior systemic therapies, for small cell lung cancer.
Post-operative radiation for the resected small cell lung cancer is acceptable per treating physician in the setting of N1 disease, but no other prior radiation for small cell lung cancer.
ECOG performance status 0-1.

Exclusion Criteria

Patients who are receiving any other investigational agents.
Concurrent enrollment in another clinical study involving investigational treatment directed to treatment of patients with small cell lung cancer.
Prior treatment with durvalumab.
History of another primary malignancy except for:
Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of IP and of low potential risk for recurrence.
Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
Superficial bladder cancer without active disease after treatment.
Low grade prostate cancer without indication for active treatment.
Adequately treated carcinoma in situ without evidence of disease.
Patients with a history of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or insufficiently treated deep venous thrombosis (DVT) within the past 3 months.
Patients with hemoptysis in excess of 2.5 mL within 2 weeks prior to the first dose of study medication.
Patients requiring concomitant therapy with phenytoin, phenobarbital, or carbamazepine.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07149363) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Small Cell Lung Cancer (SCLC) Treatment Options in Chicago, IL

If you're searching for small cell lung cancer (sclc) treatment options in Chicago, IL, this clinical trial (NCT07149363) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced small cell lung cancer (sclc) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all small cell lung cancer (sclc) clinical trials near you to find additional studies recruiting in your area.

More Lung Cancer Trials in Chicago, IL

See all lung cancer clinical trials recruiting in Chicago — not just this study.

Browse Lung Cancer Trials in Chicago →

Browse More Trials by Condition

Lung Cancer TrialsLeukemia TrialsSmall Cell Lung Cancer TrialsSpinal Muscular Atrophy TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL